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New recurring BRCA1 variant:  
An additional South African founder 
mutation?
To the Editor: Hereditary breast and ovarian cancer syndrome 
(HBOC) caused by pathogenic variants in the BRCA1 or BRCA2 genes 
accounts for 15 - 20% of the hereditary component of breast cancer. [1] 
Comprehensive genetic testing of the BRCA1 and BRCA2 genes 
remains costly in South Africa (SA) owing to the expense of high-
throughput technologies such as next-generation sequencing (NGS) 
and the complexities of downstream analysis and variant interpretation. 
Targeted testing for a subset of variants may be considered as a first-
line test in specific population groups, particularly in resource-limited 
settings. In SA, patients with Afrikaner heritage may initially be tested 
for the three known Afrikaner founder mutations.[2] If this initial screen 
is negative or patients are not of Afrikaner ancestry, comprehensive 
testing through NGS is recommended.
Full sequencing of the BRCA1 and BRCA2 genes is available 
either through an in-house NGS assay or through an international 
referral service to Invitae laboratory in the USA. Since 2015, we 
have identified eight seemingly unrelated individuals with a BRCA1 
sequence variant: BRCA1 c.45dupT (p.Asn16*). All these individuals 
were of Afrikaner ancestry (either self or clinician reported). Five of 
them were identified through PathCare in-house testing and 3 by 
Invitae laboratory. This variant has previously been reported only 
once in the literature, in a single Afrikaner individual tested by the 
National Health Laboratory Service in Johannesburg.[3]
This BRCA1 variant is not present in population databases (Exome 
Aggregation Consortium: no frequency) and has a single Invitae 
entry on ClinVar (RCV000691259). This sequence change, an 
insertion of a tyrosine molecule in exon 2 of the BRCA1 gene, results 
in a premature translational stop signal and is expected to result in 
an absent or disrupted BRCA1 protein. As this is a loss-of-function 
change, this variant has been classified as pathogenic.
Given the shared ethnic background of the patients in whom this 
variant has been detected, we propose that the BRCA1 c.45dupT 
pathogenic variant may be another Afrikaner founder mutation 
in the SA population. Including this variant in first-line founder 
mutation screening may reduce testing costs to patients and identify 
those at risk for HBOC without the need for comprehensive testing. 
Additional research into the frequency and distribution of this 
variant in the SA population is warranted.
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